Member Directory

Profile

wgoure's picture

William Goure, Ph.D.

Acumen Pharmaceuticals, Inc

Contact Information

William Goure, Ph.D.
Livermore, United States

Professional Information

Chief Operating Officer
Acumen Pharmaceuticals, Inc
http://www.acumenpharm.com

Education

B.S. Chemistry: 1976, Fort Lewis College, Durango Colorado, USA. Ph.D. Organic Chemistry: 1982, Iowa State University, Ames, Iowa, USA. Post-Doctoral Studies, Organometallic Chemistry: Colorado State University, Ft. Collins, Colorado, USA

Bio

Since August 2006, Dr. Goure has been Chief Operating Officer of Acumen Pharmaceuticals, Inc., a private, San Francisco biotechnology company focusing on discovering and developing disease modifying therapeutics for Alzheimer’s disease.

From May 2008 to December 2011, Dr. Goure was also President and interim Chief Executive Officer for Acumen, and from March 2004 to August 2006, Dr. Goure was Vice-President for Business Development and Director of Medicinal Chemistry for Acumen.

Dr. Goure has consulted for the Bill and Melinda Gates Foundation and the Foundation for the National Institute of Health on the Target Malaria and Eliminate Dengue programs and has been a business development Advisor to VM Discovery and VM Pharma of Fremont California.

Dr. Goure has over 30 years of domestic and international experience in the discovery, development, registration, and commercialization of chemical and biotechnology products.

Prior to joining Acumen, Dr. Goure was Vice-President for Commercial Development for Mendel Biotechnology, a San Francisco company focused on plant genomics.

Prior to joining Mendel, Dr. Goure worked for Monsanto Company for 17 years where he was a key member of teams that developed and commercialized Roundup Ready® soybeans, canola, cotton, corn, and sugar beets.

Financial Disclosure

Member reports the following financial or other potential conflicts of interest:

I am an officer and Chief Operating Officer of Acumen Pharmaceuticals, Inc., and preclinical drug development company developing therapeutics for the treatment and prevention of Alzheimer's Disease.